Experimental Treatment Gives Hopes to Patients with Recurrent Melanoma

A new study published in the New England Journal of Medicine suggests an experimental immune system treatment that uses the patient’s own cells might be an effective treatment for deadly skin cancers called melanomas.

A 52-year-old man with recurrent melanoma, which had already spread to a lung and a lymph node in his groin get the experimental treatment. He was a lucky man in the end because its melanoma disappeared and didn’t come back during a period of two years. The man was given an infusion of its own, fortified immune system cells called CD4+ T cells.

Scientists at the Fred Hutchinson Cancer Research Center in Seattle selected CD4+ T cells from a sample of the patient’s white blood cells. These cells were specifically programmed by the body to attack cancer. The researchers isolated those types of cells and cloned them in their lab. After several months, they infused 5 billion of the cloned cells back into the patient’s body.

“What we and others have thought might be important is that we need to give patients more of these cancer-fighting T cells which may be present in low frequency in most people,” researcher Cassian Yee, MD,  told WebMD. “You can do that either by giving them a vaccine or, in our case, we took the cells out and grew them and gave them back to him.”

“It's taken us many years to get to this point,” he added.

The treatment had no side effects. But researchers say this treatment will not always work because cancers try many different tactics to defeat the immune system, the same source noted.

T-cell therapy is a promising one although it’s hard to say if all the patients given the treatment will respond as well as the man whose cancer was halted.




© 2007 - 2008 - eNews 2.0 All Rights Reserved
 
 
T cell therapy for melanoma
By Paul Hill, (2008-06-22 16:54)
This therapy does look promising. However, it is very impractical due to the large amount of patient specific manipulation required.

Also, only one of nine patients responded.

Another therapy had Phase 2 clinical trial results presented at ASCO earlier in the month which showed much better results, with a similar low level of side effects, and is completely practical coming in an off the shelf vial.

This is called Oncovex and has given 6 complete responses (ie disease iradications, as per the one in the New England Journal paper) of 43 patients in which its been tested, with six others achieving a partial response, also by an immunlogical mechanism (in part).

However, as yet the data has not been published, other than presentation at ASCO, and so is pretty low profile at the moment.

It is much more promising than the T cell approach as it gives a higher rate of response and is completely practical.

Unlike the T cell approach, it will also start a Phase 3 clinical trial soon, and thus should rapidly become available for patients more broadly.

I suggest that those who are interested in melanoma look into this further, as the results are stunning and better than anything I've seen before. I was at ASCO, and I saw.

A google search for Oncovex will soon take you to the results
Add a new comment

T cell therapy for melanoma
By Paul Hill, (2008-06-22 16:54)
This therapy does look promising. However, it is very impractical due to the large amount of patient specific manipulation required.

Also, only one of nine patients responded.

Another therapy had Phase 2 clinical trial results presented at ASCO earlier in the month which showed much better results, with a similar low level of side effects, and is completely practical coming in an off the shelf vial.

This is called Oncovex and has given 6 complete responses (ie disease iradications, as per the one in the New England Journal paper) of 43 patients in which its been tested, with six others achieving a partial response, also by an immunlogical mechanism (in part).

However, as yet the data has not been published, other than presentation at ASCO, and so is pretty low profile at the moment.

It is much more promising than the T cell approach as it gives a higher rate of response and is completely practical.

Unlike the T cell approach, it will also start a Phase 3 clinical trial soon, and thus should rapidly become available for patients more broadly.

I suggest that those who are interested in melanoma look into this further, as the results are stunning and better than anything I've seen before. I was at ASCO, and I saw.

A google search for Oncovex will soon take you to the results

Nickname: *
Title (max 255 chars): *
Comment (max 5000 chars): *
Enter the text you see in the image: *
can't read? refresh code Enter the code shown:
Fields marked with an asterisk (*) are required.

 
 
Ashley Dupre Finally Speaks Out about Relationship with Eliot Spitzer
Ashley Dupre, 23, the prostitute from the call center who cost Eliot Spitzer her governor position opened up in front of his wife and apologized. She told People...

Ashley Dupre Finally Speaks Out about Relationship with Eliot Spitzer
 

dotclear
dotclear